For more than a year, the drug maker brushed aside repeated warnings from a whistleblower about systemic fraud and corruption in its China operations. The case was fueled by missed clues, poor communication and a willful avoidance of the facts.
For more than a year, the drug maker brushed aside repeated warnings from a whistleblower about systemic fraud and corruption in its China operations. The case was fueled by missed clues, poor communication and a willful avoidance of the facts.